Arrowhead's Hep B Phase 2a Topline Data Imminent - 'Transformational' Potential
- CEO says Phase 2a topline data for Hep B candidate ARC-520 to come in Q3.
- There are 350M-400M people infected with chronic hepatitis B (2X the Hep C market). CEO says functional cure for hepatitis B would be "transformational".
- Bullish climate for drugs targeting diseases of the liver.